* Q1 EPS $0.13 vs est $0.11
* Q1 revenue up 37 percent
April 21 (Reuters) - Cubist Pharmaceuticals Inc CBST.O reported a first-quarter profit that beat analysts’ average estimate, helped by a 31 percent rise in U.S. sales of Cubicin, its antibiotic injection to treat bacterial infections.
The biopharmaceutical company earned $7.8 million, or 13 cents a share, compared with $9.7 million, or 17 cents a share, in the year-ago period.
Revenue came in at $121.1 million. The company reported net sales of Cubicin in the United States of $112.4 million.
Analysts on average were expecting revenue of $127.9 million, according to Reuters Estimates.
For the alerts, please double-click [ID:nWNAB5750] (Reporting by Shailesh Kuber in Bangalore; Editing by Himani Sarkar)